Seagen To Surge Ahead As ADCs Become Frontline Cancer Therapies

Padcev Plus Keytruda To Become Bladder Cancer Blockbuster

 
• By Andrew McConaghie
  
Seagen
Adcetris and Padcev will be the company's two main growth drivers this year. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business